PL378754A1 - 2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6 - Google Patents
2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6Info
- Publication number
- PL378754A1 PL378754A1 PL378754A PL37875404A PL378754A1 PL 378754 A1 PL378754 A1 PL 378754A1 PL 378754 A PL378754 A PL 378754A PL 37875404 A PL37875404 A PL 37875404A PL 378754 A1 PL378754 A1 PL 378754A1
- Authority
- PL
- Poland
- Prior art keywords
- modulators
- substituted tetrahydroisoquinolines
- tetrahydroisoquinolines
- substituted
- Prior art date
Links
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45151603P | 2003-03-03 | 2003-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL378754A1 true PL378754A1 (pl) | 2006-05-15 |
Family
ID=32962598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378754A PL378754A1 (pl) | 2003-03-03 | 2004-02-23 | 2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7196088B2 (pl) |
| EP (1) | EP1601358B1 (pl) |
| JP (1) | JP2006515341A (pl) |
| KR (1) | KR100751604B1 (pl) |
| CN (1) | CN100395237C (pl) |
| AR (1) | AR043436A1 (pl) |
| AT (1) | ATE381334T1 (pl) |
| AU (1) | AU2004216813B2 (pl) |
| BR (1) | BRPI0407976A (pl) |
| CA (1) | CA2517146A1 (pl) |
| CL (1) | CL2004000382A1 (pl) |
| DE (1) | DE602004010791T2 (pl) |
| ES (1) | ES2297386T3 (pl) |
| MX (1) | MXPA05009359A (pl) |
| PL (1) | PL378754A1 (pl) |
| RU (1) | RU2327689C2 (pl) |
| TW (1) | TW200426145A (pl) |
| WO (1) | WO2004078176A1 (pl) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1408976B3 (en) | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
| PT1497266E (pt) | 2002-03-27 | 2008-09-10 | Glaxo Group Ltd | Derivados de quinolina e sua utilização como ligandos 5-ht6 |
| MXPA06000795A (es) | 2003-07-22 | 2006-08-23 | Arena Pharm Inc | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo. |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| US20080051387A1 (en) * | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| MX2009005825A (es) * | 2006-12-27 | 2009-06-16 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa. |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| ATE499099T1 (de) * | 2007-07-19 | 2011-03-15 | Esteve Labor Dr | Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente |
| TW200927731A (en) | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
| EA019085B1 (ru) | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны |
| JP5433582B2 (ja) | 2007-11-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用 |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010025890A1 (en) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| CA2760259C (en) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5634506B2 (ja) | 2009-05-12 | 2014-12-03 | ジャンセン ファーマシューティカルズ， インコーポレイテッド | １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
| PE20180462A1 (es) | 2015-07-06 | 2018-03-06 | Gilead Sciences Inc | Moduladores cot y metodos de uso de los mismos |
| CA2992518A1 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CN115397511A (zh) | 2020-03-30 | 2022-11-25 | 吉利德科学公司 | Cot抑制剂化合物(s)-6-(((1-(双环[1.1.1]戊-1-基)-1h-1,2,3-三唑-4-基)2-甲基-1-氧代-1,2-二氢异喹啉-5-基)甲基)))氨基8-氯-(新戊基氨基)喹啉-3-甲腈的固体形式 |
| EP4126862A1 (en) | 2020-04-02 | 2023-02-08 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586794T2 (de) | 1984-12-21 | 1993-05-27 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
| DK148392D0 (da) | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| IL110172A (en) | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
| US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US6417362B1 (en) * | 1997-05-30 | 2002-07-09 | Meiji Seika Kaisha, Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
| US6316450B1 (en) * | 1997-07-11 | 2001-11-13 | Smithkline Beecham P.L.C. | Compounds |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| AU779550B2 (en) * | 1999-04-09 | 2005-01-27 | Meiji Seika Kaisha Ltd. | Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same |
| WO2001032660A1 (en) * | 1999-11-05 | 2001-05-10 | Nps Allelix Corp. | Compounds having 5-ht6 receptor antagonist activity |
| US7157463B2 (en) | 2001-01-23 | 2007-01-02 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
| JP2005501019A (ja) * | 2001-06-15 | 2005-01-13 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体 |
| JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
-
2004
- 2004-02-23 DE DE602004010791T patent/DE602004010791T2/de not_active Expired - Lifetime
- 2004-02-23 KR KR1020057016314A patent/KR100751604B1/ko not_active IP Right Cessation
- 2004-02-23 CA CA002517146A patent/CA2517146A1/en not_active Abandoned
- 2004-02-23 BR BRPI0407976-0A patent/BRPI0407976A/pt not_active IP Right Cessation
- 2004-02-23 PL PL378754A patent/PL378754A1/pl not_active Application Discontinuation
- 2004-02-23 EP EP04713547A patent/EP1601358B1/en not_active Expired - Lifetime
- 2004-02-23 WO PCT/EP2004/001751 patent/WO2004078176A1/en active IP Right Grant
- 2004-02-23 RU RU2005130514/04A patent/RU2327689C2/ru not_active IP Right Cessation
- 2004-02-23 AU AU2004216813A patent/AU2004216813B2/en not_active Ceased
- 2004-02-23 MX MXPA05009359A patent/MXPA05009359A/es active IP Right Grant
- 2004-02-23 ES ES04713547T patent/ES2297386T3/es not_active Expired - Lifetime
- 2004-02-23 CN CNB2004800058420A patent/CN100395237C/zh not_active Expired - Fee Related
- 2004-02-23 AT AT04713547T patent/ATE381334T1/de not_active IP Right Cessation
- 2004-02-23 JP JP2006500040A patent/JP2006515341A/ja not_active Ceased
- 2004-02-26 TW TW093104922A patent/TW200426145A/zh unknown
- 2004-02-27 CL CL200400382A patent/CL2004000382A1/es unknown
- 2004-03-01 AR ARP040100639A patent/AR043436A1/es not_active Application Discontinuation
- 2004-03-02 US US10/791,578 patent/US7196088B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2517146A1 (en) | 2004-09-16 |
| EP1601358A1 (en) | 2005-12-07 |
| ATE381334T1 (de) | 2008-01-15 |
| KR100751604B1 (ko) | 2007-08-22 |
| RU2005130514A (ru) | 2006-05-10 |
| CN1756550A (zh) | 2006-04-05 |
| US7196088B2 (en) | 2007-03-27 |
| CL2004000382A1 (es) | 2005-01-07 |
| DE602004010791T2 (de) | 2008-12-04 |
| AU2004216813A1 (en) | 2004-09-16 |
| JP2006515341A (ja) | 2006-05-25 |
| CN100395237C (zh) | 2008-06-18 |
| RU2327689C2 (ru) | 2008-06-27 |
| WO2004078176A1 (en) | 2004-09-16 |
| TW200426145A (en) | 2004-12-01 |
| KR20050106069A (ko) | 2005-11-08 |
| AU2004216813B2 (en) | 2008-09-11 |
| ES2297386T3 (es) | 2008-05-01 |
| US20040180874A1 (en) | 2004-09-16 |
| MXPA05009359A (es) | 2005-11-04 |
| DE602004010791D1 (de) | 2008-01-31 |
| AR043436A1 (es) | 2005-07-27 |
| BRPI0407976A (pt) | 2006-03-07 |
| EP1601358B1 (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378754A1 (pl) | 2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6 | |
| IL177798A0 (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | |
| HK1093503A1 (en) | Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors | |
| IL163928A0 (en) | Pyridinoylpiperidines as 5-htf agonists | |
| SI1699795T1 (sl) | Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati | |
| AP2005003343A0 (en) | Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors | |
| HK1090368A1 (en) | 2,3,6-trisubstituted-4-pyrimidone derivatives | |
| PL378025A1 (pl) | Pochodne bifenylowe | |
| AU2003259025A8 (en) | Electrosurgical specimen-collection system | |
| PL372902A1 (pl) | Nowe zastosowanie | |
| IL196021A0 (en) | Pyrazolopyridine derivatives uses | |
| HK1088003A1 (en) | 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and-2-sulfonamide derivatives as cb1 modulators | |
| AU2003256500A8 (en) | Knee balancing block | |
| IL183706A0 (en) | 2,4(4,6) pyrimidine derivatives | |
| PL370408A1 (pl) | Nowe pochodne sulfonoamidowe jako ligandy receptora D3 | |
| IL172894A0 (en) | Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | |
| IL172891A0 (en) | Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | |
| AU2003296660A1 (en) | Copolyamides | |
| GB0328937D0 (en) | Lifeline trolley | |
| ZA200408281B (en) | Isoquinoline derivatives. | |
| IL173445A (en) | 6-(1,1-difluoroalkyl)-4-aminopicolinates for use as herbicides | |
| IL154067A0 (en) | Sprinkler system | |
| GB0300249D0 (en) | Communication system for down hole use | |
| EP1711189A4 (en) | AZALIDE DERIVATIVES 8A 6,11-3C-BICYCLIC | |
| EP1578441A4 (en) | Polyphosphazene immunostimulants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |